Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 2006

View Archived Issues

New anti-HIV fusion protein from FusoGen

Biologic responses observed in RA patients treated with TACI-Ig

VX-950 plus PEG-IFN reduces plasma viral RNA in chronic genotype 1 HCV patients

Protein Design Labs changes name to PDL BioPharma

Lilly to develop Kyowa Hakko's mitotic kinesin Eg5 inhibitor

KAI Pharmaceuticals and Sankyo sign agreement for KAI-9803

Applied Biosystems transfers interest in Celera Diagnostics to Celera Genomics

Novartis will not make offer to acquire Berna Biotech

HIV integrase inhibitor GS-9137 completes phase I/II study

Data support bioequivalence of new Sustiva/Truvada fixed-dose formulation

Enrollment open in dose-ranging study of TBC-3711 in resistant hypertension

New approval for Emend

FMPD: Lilly's new candidate for psychosis

Alkermes and Lilly sign agreement for inhaled PTH development

AVN-944 begins phase I study in advanced hematological malignancies

Novel SARMs subject of Merck & Co. patent

NIAID grant supports influenza A vaccine development at Juvaris

Novel agents for treating neurological disorders disclosed in recent sanofi-aventis patent

Evotec licenses two MAO-B inhibitors from Roche for Alzheimer's disease

Phase I study evaluates IPI-504 in patients with GIST

European orphan drug status for denufosol tetrasodium in cystic fibrosis

Tranzyme cleared to begin phase I study of TZP-101

Tesmilifene studied with docetaxel in rapidly progressing metastatic breast cancer

Replidyne submits Orapem NDA

Menarini's promising new low-dose candidate for bronchoconstriction

Oxazolidinones with Gram-negative activity synthesized

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...